Relay Therapeutics, Inc.

NASDAQ:RLAY

Biotechnology

Healthcare
$16.51 +2.63%

+$0.41 today

Market cap
$3.65B
Beta
1.75
P/E (TTM)
-10.5
EPS (TTM)
-$1.52
52W Low $3.03High $17.47

Volume 2.43M

Average 3.70M

RLAY Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Relay Therapeutics, Inc.NASDAQ: RLAY

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin growth accelerates

Q2 FY2026 selling, general & admin of $14.69M rose 6.8% year over year, ahead of the -29.7% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 33.2% from the prior quarter. Over 3 fiscal years it compounded at -6.5% a year.

Context

  • Selling, general & admin amounted to 369.3% of revenue in FY2025, down 432.5 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 8 analysts of $166.39M (+193.4%) for the fiscal year ending Dec 2026, a step up from the -29.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$14.69M+33.2% QoQ
Last fiscal yearDec 2025
$56.71M-29.3% YoY
LTMJun 2026
$51.18M-29.7% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.8%+119.6%+112.8 pp
1 year-29.3%+193.4%+222.7 pp
3-year CAGR-6.5%+82.4%+88.9 pp
5-year CAGR+168.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
56.71M USD
Year-over-year change
-29.3%
4-year CAGR
-1.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How RLAY compares with its peers on the latest reported figures

  • RLAY's LTM Jun 2026 selling, general & admin of $51.18M is the 6th highest of the 11 companies compared; the peer median is $56.62M.
  • Its year-over-year change of -29.7% is the lowest of 11, against a peer median of +39.3%.
  • Selling, general & admin amounts to 494.5% of revenue for RLAY, versus a peer median of 51.4%.
RLAY Competitors Peer median
Selling, General & Admin for RLAY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RVMDRevolution Medicines, Inc.LTM Jun 2026$328.54M +157.1%+66.4%—
NRIXNurix Therapeutics, Inc.LTM Aug 2026$78.21M +57.0%+11.6%11.1%
TNGXTango Therapeutics, Inc.LTM Sep 2026$76.77M +79.2%+11.4%—
KYMRKymera Therapeutics, Inc.LTM Jun 2026$75.77M +15.3%+15.9%72.2%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$69.19M +65.4%+42.7%30.7%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$51.18M -29.7%-6.5%494.5%
ERASErasca, Inc.LTM Sep 2026$44.05M +16.1%+5.3%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$33.29M +12.6%+9.8%—
TYRATyra Biosciences, Inc.LTM Mar 2026$31.48M +21.6%+23.3%—
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$27.19M +59.1%+55.2%—
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$21.38M -22.5%-9.9%127.9%
Peer median (excluding RLAY) $56.62M+39.3%+13.7%51.4%

Competitors are the stored peer set for RLAY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.03M1.38M25.55M10.01M15.36M
Cost of Revenue169.39M243.01M326.39M315.44M3.56M
Gross Profit(166.36M)(241.62M)(300.84M)(305.43M)11.8M
Gross Margin-5492.2%-17496.3%-1177.6%-3052.2%76.8%
Research & Development295.65M246.36M330.02M319.09M261.38M
Selling, General & Admin59.75M69.33M78.58M80.24M56.71M
Operating Expenses198.34M57.65M72.16M67.03M314.54M
Depreciation & Amortization3.93M4.13M5.27M5.46M3.56M
EBITDA(223.08M)(306.82M)(374.15M)(380.21M)(272.92M)
EBITDA Margin-7364.9%-22217.4%-1464.6%-3799.4%-1777.4%
Operating Income(364.7M)(299.28M)(373M)(372.47M)(302.74M)
Operating Margin-12040.2%-21670.9%-1460.1%-3722.1%-1971.6%
Interest Income830K8.79M31.05M34.75M27.04M
Interest Expense00000
Other Income / Expenses826K8.77M31.03M34.76M26.26M
Income Before Tax(363.87M)(290.51M)(341.97M)(337.71M)(276.48M)
Pre-Tax Margin-12012.9%-21036.1%-1338.7%-3374.7%-1800.6%
Income Tax Expense00000
Net Income(363.87M)(290.51M)(341.97M)(337.71M)(276.48M)
Net Margin-12012.9%-21036.1%-1338.7%-3374.7%-1800.6%
EPS (Basic)(3.82)(2.59)(2.79)(2.36)(1.61)
EPS (Diluted)(3.82)(2.59)(2.79)(2.36)(1.61)
Weighted Avg Shares95.14M112.23M122.58M142.87M171.59M
Weighted Avg Shares (Diluted)95.14M112.23M122.58M142.87M171.59M

Relay Therapeutics, Inc.

NASDAQ:RLAY

Intrinsic Alpha fair value

Locked

Current Price

$16.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.